Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
RPRX

RPRX - Royalty Pharma PLC Stock Price, Fair Value and News

$40.41-0.33 (-0.81%)
Market Closed

54/100

RPRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

54/100

RPRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$39.71

Target 3M

$40.24

Target 6M

$40.08

RPRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RPRX Price Action

Last 7 days

1.7%

Last 30 days

3.4%

Last 90 days

9.4%

Trailing 12 Months

26.5%

RPRX RSI Chart

RPRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RPRX Valuation

Market Cap

17.5B

Price/Earnings (Trailing)

22.82

Price/Sales (Trailing)

7.43

EV/EBITDA

15.94

Price/Free Cashflow

7.26

RPRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$39.71

Target 3M

$40.24

Target 6M

$40.08

RPRX Fundamentals

RPRX Revenue

Revenue (TTM)

2.3B

Rev. Growth (Yr)

7.9%

Rev. Growth (Qtr)

5.29%

RPRX Earnings

Earnings (TTM)

765.0M

Earnings Growth (Yr)

-47.02%

Earnings Growth (Qtr)

855.12%

RPRX Profitability

EBT Margin

55.43%

Return on Equity

7.95%

Return on Assets

3.95%

Free Cashflow Yield

13.78%

RPRX Investor Care

Dividend Yield

2.15%

Dividend/Share (TTM)

0.87

Buy Backs (1Y)

3.52%

Diluted EPS (TTM)

1.76

RPRX Alerts

  • 2 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20252.3B2.3B2.3B0
20242.2B2.2B2.3B2.3B
20232.4B2.4B2.3B2.4B
20222.3B2.3B2.2B2.2B
20212.4B2.4B2.5B2.3B
20201.2B1.6B1.6B1.9B
20191.2B1.4B1.6B1.8B
2018000983.2M
2017000877.9M
Get all data in R, Python etc through our Historical Stock Data APIs

About Royalty Pharma PLC

RPRX
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
0
 CEO
 WEBSITEroyaltypharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology

Royalty Pharma PLC Frequently Asked Questions

RPRX is the stock ticker symbol of Royalty Pharma PLC. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Royalty Pharma PLC is 17.45 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check RPRX's fair value in chart for subscribers.

The fair value guage provides a quick view whether RPRX is over valued or under valued. Whether Royalty Pharma PLC is cheap or expensive depends on the assumptions which impact Royalty Pharma PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RPRX.

As of Wed Jan 28 2026, RPRX's PE ratio (Price to Earnings) is 22.82 and Price to Sales (PS) ratio is 7.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RPRX PE ratio will change depending on the future growth rate expectations of investors.